financetom
Business
financetom
/
Business
/
Elf Beauty lifts annual forecasts as cosmetic, skincare demand holds up
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Elf Beauty lifts annual forecasts as cosmetic, skincare demand holds up
Aug 8, 2024 1:31 PM

By Granth Vanaik

(Reuters) - Elf Beauty ( ELF ) raised annual sales and profit forecasts after topping first-quarter estimates on Thursday, as more customers visited stores and websites to buy its affordable cosmetics and skincare products.

Beauty company Elf, like its peers in the segment, has sustained the post-pandemic boom in demand, as low-cost products from its brands such as Naturium, Skin, and Cosmetics continue to attract customers, including those having strained budgets due to a sticky inflation.

Retailers, such as Target, which house Elf's products, have also seen sales surge for beauty products in recent months.

"We have seen consumers are getting choosier, but they're choosing Elf," CEO Tarang Amin told Reuters.

Elf's stock, however, has dropped about 14% quarter-to-date, after investors raised concerns around possibility of rising tariffs on imports of its nearly 80% finished products manufactured in China and higher ocean freight costs, among other factors.

CEO Amin said that an increase in tariffs on imports from China, if Republican presidential candidate Donald Trump comes to power, would mostly impact the company in fiscal 2026.

Earlier this year, Trump had floated the idea of imposing tariffs on China again if he wins the presidential election in November and said the rate for such tariffs could exceed 60%.

"We don't like 60% tariff just because we feel it is a tax on American consumers," Amin said, adding, the tariffs impact would be addressed by raising product prices and diversifying supply chain operations.

Elf now sees 2025 sales to be between $1.28 billion and $1.30 billion, compared to previous expectations of $1.23 billion and $1.25 billion.

It now expects annual adjusted per-share profit to be between $3.36 and $3.41, versus prior projections of $3.20 and $3.25.

Net sales rose 50% to $324.5 million in the quarter ended June 30, beating estimates of about $304.7 million. Adjusted profit of $1.10 per share also topped LSEG expectations of 84 cents.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug
Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug
May 15, 2024
04:26 AM EDT, 05/15/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said Tuesday that the latter has initiated a rolling submission of a biologics license application to the US Food and Drug Administration for lecanemab-irmb subcutaneous autoinjector as a weekly maintenance treatment for early Alzheimer's disease. The application came after the treatment, commercially known as Leqembi, was granted FDA fast-track...
Novonix Signs Testing, Development Deal With Volkswagen-Owned PowerCo
Novonix Signs Testing, Development Deal With Volkswagen-Owned PowerCo
May 15, 2024
04:32 AM EDT, 05/15/2024 (MT Newswires) -- Novonix ( NVX ) said late Tuesday it signed a non-exclusive testing and development agreement with Volkswagen-owned PowerCo to come up with synthetic graphite anode materials for electric vehicle batteries. The companies could later enter into a supply agreement for the products developed under the deal, Novonix ( NVX ) said. Financial terms...
Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
May 15, 2024
04:24 AM EDT, 05/15/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Arcutis Biotherapeutics' ( ARQT ) shares surged more than 20% in premarket activity on Wednesday after the company reported a narrower loss and handily beat market expectations for sales. The company reported a Q1 loss late Tuesday of $0.32 per diluted...
New York Community Bancorp to Sell $5 Billion in Mortgage Warehouse Loans to JPMorgan Chase Bank
New York Community Bancorp to Sell $5 Billion in Mortgage Warehouse Loans to JPMorgan Chase Bank
May 15, 2024
04:12 AM EDT, 05/15/2024 (MT Newswires) -- New York Community Bancorp ( NYCB/PU ) said Tuesday it has entered into a commitment letter to sell about $5 billion in mortgage warehouse loans to JPMorgan Chase Bank. The sale is expected to close in Q3. Shares of New York Community Bancorp gained almost 6% in after-market hours on Tuesday. Price: 4.1200,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved